B
Berry Oncology
Genomic testing and early screening for cancer
About Berry Oncology
Berry Oncology, established in 2017 as a subsidiary of Berry Genomics, is a company focused on cancer diagnostics through genomic testing. The company's stated mission is to “diagnose all cancers early, treat all patients precisely”. Its offerings span genetic susceptibility analysis, early cancer screening, companion diagnostics for targeted and immune therapies, and treatment response monitoring.
Read full description
The company's core technology is its HIFI platform, which utilizes liquid biopsy and multi-omics based on next-generation sequencing (NGS) to detect cancer signals. One of their key products is the "HIFI Pan-Cancer Screening," designed to detect six high-incidence cancers in China: lung, esophageal, gastric, liver, pancreatic, and colorectal cancer. This product analyzes cell-free DNA (cfDNA) through whole-genome sequencing (WGS). The company has reported a sensitivity of 87.58% and a specificity of 99.09% for this multi-cancer screening product. In 2020, Berry Oncology launched an early screening product for liver cancer named “Lai Si Ning”.
Led by CEO Jun Zhou, Berry Oncology has focused its product design on the specific tumorigenic characteristics of the Chinese population. The company has engaged in strategic partnerships to expand its reach. In 2021, it partnered with Alibaba Health to build a comprehensive cancer screening and prevention ecosystem, combining internet services with its early screening technology. The company has also collaborated with MGI Tech to enhance the commercialization and cost-effectiveness of its early cancer screening products. To support its research and product development, Berry Oncology has secured significant funding, including a Series B1 round of nearly $100 million in 2021.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Fuzhou City, China
- Open positions
- None listed
- Dealroom signal
- 24.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biomarkers, Genetics and genomics, Health Diagnostics, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Latest news
Press, funding announcements and product moves mentioning Berry Oncology.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2021 | $99M | $397M | Legend Capital · Qiming Venture Partners · E-Fund · Zhongjin Qichen Industry Equity Investment Fund | — |
| SERIES AOther financing | Mar 2020 | $9.6M | $39M | Undisclosed | — |
Growth signals
Latest recorded traffic for Berry Oncology is 180 monthly website visits, up 1700% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Qiming Venture Partners
Boyu Capital- CCChina Merchants Capital
Legend Capital
E-Fund- ZFZhongjin Qichen Industry Equity Investment Fund
- FMFujian Venture Investment Management
Xiamen C&D Emerging Industry Equity Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Berry Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Berry Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.